Barclays Cuts European Chemical Stocks on Inflation Fears

Barclays Adjusts Outlook for European Ingredients Sector

Barclays has downgraded three major European consumer ingredients stocks and reduced earnings forecasts across the sector. The move reflects concerns that a new inflation shock, driven by the Middle East conflict, will delay a projected volume recovery initially expected in 2026.

Specific Stock Downgrades and Forecast Cuts

The bank downgraded Givaudan to Equal Weight from Overweight, Barry Callebaut to Underweight from Equal Weight, and Corbion to Equal Weight from Overweight. Consequently, EBITDA forecasts for 2026 have been lowered by 2-7% for most companies covered, with the most significant reductions affecting Givaudan, Symrise, and Barry Callebaut.

Inflation Concerns Reshape Investor Expectations

The primary driver for this reset is the anticipated impact of renewed energy-driven inflation. This development forces a reassessment of the sector's growth trajectory, pushing back the timeline for a demand recovery that investors had been anticipating. Price targets were also trimmed for most stocks in its coverage universe.

Outlook and Key Factors to Watch

The downgrades signal a more cautious outlook for the European consumer ingredients market. Investors will be closely monitoring energy prices and geopolitical developments in the Middle East as key indicators for the sector's future performance and the timing of any potential recovery.

FAQ

Q: Which companies did Barclays downgrade?
A: Barclays downgraded Givaudan, Barry Callebaut, and Corbion.

Q: Why did Barclays downgrade these stocks?
A: The downgrades are due to an expected inflation shock linked to the Middle East conflict, which is predicted to delay the recovery of sales volumes.

Source: Investing.com